Cytokinetics, Incorporated

NASDAQ:CYTK

Biotechnology

Healthcare
$51.32 +3.86%

+$2.90 today

Market cap
$7.15B
Beta
0.43
P/E (TTM)
-11.6
EPS (TTM)
-$6.73
52W Low $31.99High $80.20

Volume 1.59M

Average 2.37M

CYTK Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Cytokinetics, IncorporatedNASDAQ: CYTK

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue declines year over year

Q2 FY2026 revenue of $31.91M fell 52.2% year over year, behind the -17.2% change in trailing-twelve-month revenue. Sequentially, it rose 64.9% from the prior quarter. Over 3 fiscal years it compounded at -2.4% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 15 analysts of $162.34M (+84.4%) for the fiscal year ending Dec 2026, a slowdown from the +376.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$31.91M+64.9% QoQ
Last fiscal yearDec 2025
$88.04M+376.6% YoY
LTMJun 2026
$70.96M-17.2% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-52.2%+2063.3%+2115.5 pp
1 year+376.6%+84.4%-292.2 pp
3-year CAGR-2.4%+118.8%+121.1 pp
5-year CAGR+94.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
88.04M USD
Year-over-year change
+376.6%
4-year CAGR
+5.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How CYTK compares with its peers on the latest reported figures

  • CYTK's LTM Jun 2026 revenue of $70.96M is the highest of the 3 companies compared; the peer median is $9.42M.
CYTK Competitors Peer median
Revenue for CYTK and competitors
Company Period LTM YoY 3-year CAGR
CYTKCytokinetics, IncorporatedLTM Jun 2026$70.96M -17.2%-2.4%
RNAAtrium Therapeutics, Inc.FY2025$18.62M ——
TNYATenaya Therapeutics, Inc.LTM Mar 2026$225K ——
KARDKardigan, Inc.—— ——
Peer median (excluding CYTK) $9.42M——

Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue70.43M94.59M7.53M18.47M88.04M
Cost of Revenue159.94M240.81M330.12M339.41M10.13M
Gross Profit(89.51M)(146.23M)(322.59M)(320.93M)77.91M
Gross Margin-127.1%-154.6%-4284.1%-1737.2%88.5%
Research & Development159.94M240.81M330.12M339.41M405.9M
Selling, General & Admin96.8M177.98M173.61M215.31M284.27M
Operating Expenses96.8M177.98M173.61M215.31M690.17M
Depreciation & Amortization2.28M5.81M11.89M9.53M10.13M
EBITDA(183.71M)(331.99M)(456.68M)(493.48M)(774.83M)
EBITDA Margin-260.8%-351.0%-6064.9%-2671.2%-880.1%
Operating Income(186.31M)(324.2M)(496.21M)(536.25M)(612.26M)
Operating Margin-264.5%-342.8%-6589.7%-2902.7%-695.4%
Interest Income331K11.34M27.63M51.53M48.42M
Interest Expense29.33M51.16M57.67M86.51M103.87M
Other Income / Expenses(29M)(64.75M)(30.04M)(53.28M)(172.7M)
Income Before Tax(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Pre-Tax Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
Income Tax Expense00000
Net Income(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Net Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
EPS (Basic)(2.80)(4.33)(5.45)(5.26)(6.54)
EPS (Diluted)(2.80)(4.33)(5.45)(5.26)(6.54)
Weighted Avg Shares76.89M89.83M96.52M111.98M120.02M
Weighted Avg Shares (Diluted)76.89M89.83M96.52M111.98M120.1M

Cytokinetics, Incorporated

NASDAQ:CYTK

Intrinsic Alpha fair value

Locked

Current Price

$51.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.